Teamwork Financial Advisors LLC Makes New Investment in Natera, Inc. $NTRA

Teamwork Financial Advisors LLC purchased a new position in shares of Natera, Inc. (NASDAQ:NTRA) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 10,815 shares of the medical research company’s stock, valued at approximately $2,936,000.

A number of other institutional investors have also modified their holdings of NTRA. FNY Investment Advisers LLC purchased a new stake in shares of Natera in the 2nd quarter valued at $59,000. Elevation Wealth Partners LLC acquired a new position in Natera during the 2nd quarter worth about $30,000. PensionDanmark Pensionsforsikringsaktieselskab boosted its holdings in Natera by 9.8% during the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 13,770 shares of the medical research company’s stock valued at $3,738,000 after acquiring an additional 1,230 shares during the period. Assenagon Asset Management S.A. boosted its holdings in Natera by 314.4% during the 2nd quarter. Assenagon Asset Management S.A. now owns 250,869 shares of the medical research company’s stock valued at $68,098,000 after acquiring an additional 190,334 shares during the period. Finally, GAMMA Investing LLC grew its position in Natera by 17.3% in the 2nd quarter. GAMMA Investing LLC now owns 1,225 shares of the medical research company’s stock valued at $333,000 after acquiring an additional 181 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. Wolfe Research initiated coverage on shares of Natera in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 price target on the stock. The Goldman Sachs Group assumed coverage on shares of Natera in a research note on Friday, June 5th. They issued a “neutral” rating and a $245.00 price objective for the company. Morgan Stanley upped their target price on shares of Natera from $250.00 to $310.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. Robert W. Baird set a $348.00 target price on shares of Natera in a report on Friday. Finally, Evercore reiterated an “outperform” rating and set a $300.00 target price on shares of Natera in a report on Monday, July 6th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $299.65.

Natera Price Performance

NTRA stock opened at $322.10 on Friday. The business’s 50-day moving average is $254.03 and its two-hundred day moving average is $223.79. The firm has a market capitalization of $46.13 billion, a P/E ratio of -236.84 and a beta of 1.51. Natera, Inc. has a 1 year low of $149.38 and a 1 year high of $323.01.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. Natera had a negative return on equity of 11.82% and a negative net margin of 7.11%.The business had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. During the same period in the previous year, the company posted ($0.74) earnings per share. The business’s revenue for the quarter was up 37.7% on a year-over-year basis. On average, analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Natera News Roundup

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Revenue significantly exceeded expectations. Natera generated $752.8 million in second-quarter revenue, up 37.7% year over year and well above the $661.2 million analyst consensus. Gross margin also improved to 64.5% from 63.4% a year earlier. Natera Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The quarterly loss narrowed. Natera reported a loss of $0.47 per share, compared with a $0.74-per-share loss in the prior-year quarter, and better than the $0.49 loss expected by analysts. The result suggests continued operating improvement despite the company remaining unprofitable. Natera Reports Q2 Loss and Beats Revenue Estimates
• Positive Sentiment: Management raised its fiscal 2026 revenue outlook to approximately $2.9 billion, above the roughly $2.8 billion consensus estimate. The higher guidance points to sustained momentum across Natera’s reproductive health, oncology, and transplant-testing businesses.
• Positive Sentiment: JPMorgan raised its price target on NTRA from $315 to $360 and maintained an “overweight” rating, signaling that the bank sees additional upside after the earnings beat. Benzinga
• Positive Sentiment: Natera submitted its Signatera bladder-cancer test to Japan’s PMDA for approval as a companion diagnostic. Clearance could expand the company’s international oncology market and create another source of long-term growth. Natera Submits Signatera to Japan’s PMDA
• Neutral Sentiment: Several executives sold shares under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. Because the sales were relatively small compared with their remaining holdings and were not discretionary open-market disposals, they provide limited negative information.
• Negative Sentiment: Natera remains unprofitable, and its very high valuation leaves the shares vulnerable to profit-taking if growth slows or future results fail to exceed elevated expectations. Commentary identifying NTRA as entering a potential profit-taking zone highlights this near-term risk. IBD 50 Stock Natera Profit-Taking Zone

Insider Activity at Natera

In other news, Director Gail Boxer Marcus sold 11,000 shares of the firm’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $217.21, for a total value of $2,389,310.00. Following the sale, the director directly owned 6,183 shares in the company, valued at approximately $1,343,009.43. This trade represents a 64.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Steven Leonard Chapman sold 41,124 shares of Natera stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $221.03, for a total transaction of $9,089,637.72. Following the sale, the chief executive officer directly owned 108,743 shares of the company’s stock, valued at approximately $24,035,465.29. This trade represents a 27.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 181,045 shares of company stock worth $41,330,968 over the last ninety days. 5.05% of the stock is currently owned by insiders.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.